
Paul Bresge
CEO
Prior to co-founding Ray Therapeutics, Paul Bresge has been part of the regenerative medicine community for more than a decade, including CEO of jCyte, a cell therapy company for blinding diseases, where he played a critical role in the Company from its inception through a successful phase 2b study in patients with retinitis pigmentosa. He brings more than 30 years of experience and a proven track record of success in creating shareholder value. He has led cross-functional teams to execute and close highly complex transactions, including jCyte’s $252M licensing deal with Santen Pharmaceutical in 2020. Mr. Bresge is very passionate about bringing therapies to patients.